Journals / İnfeksiyon Dergisi / 2005 / Cilt: 19 - Sayı: 1

Relationship of serum malondialdehyde levels with histopathology and interferon treatment in HBeAg positive chronic hepatitis B cases

HBeAg pozitif kronik hepatit B olgularında serum malondiyaldehit düzeyinin karaciğer histopatolojisi ve interferon tedavisi ile ilişkisi

Pages
5–9
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, post-treatment MDA levels were found to be significantly lower than the pre-treatment values in the patients (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purpose of the present study was to investigate the relation of serum malondialdehyde (MDA) levels, MDA and viral burden to necroinflammation öf liver and fibrosis and effects of interferon therapy on MDA in patients with chronic hepatitis B.
📊
Key Findings & Data:Forty-four chronic hepatitis B patients and 44 healthy volunteers were enrolled in the study.
💡
Conclusion & Impact:However, post-treatment MDA levels were found to be significantly lower than the pre-treatment values in the patients (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The purpose of the present study was to investigate the relation of serum malondialdehyde (MDA) levels, MDA and viral burden to necroinflammation öf liver and fibrosis and effects of interferon therapy on MDA in patients with chronic hepatitis B. Forty-four chronic hepatitis B patients and 44 healthy volunteers were enrolled in the study. Fifteen cases who could be treated at the authors' clinic were re-evaluated at the end of the therapy. At the end of the study, together with the serological markers relating to viral aetiology, alanin aminotransferase (ALT), aspartat aminotransferase (AST), serum MDA and hepatitis B virus-DNA (HBV-DNA) levels were determined in the study group. Histopathological findings in the liver were scored as necroinflammatory activity (grade) and fibrosis (stage) according to the Knodell scoring scale. The malondialhyde levels were significantly higher-in the chronic hepatitis B patients compared to the healthy controls (p0.05). However, post-treatment MDA levels were found to be significantly lower than the pre-treatment values in the patients (p

Özet

Bu çalışmada; kronik hepatit B'li olgularda serum malondiyaldehit (MDA) düzeyinin, MDA düzeyi ile viral yük, karaciğerin nekro-inflamasyonu ve fibroziz arasındaki olası ilişkinin ve interferon tedavisi gören olgularda MDA düzeyinin nasıl etkilendiğinin araştırılması amaçlanmıştır. Çalışmaya 44 kronik hepatit B olgusu ile 44 sağlıklı gönüllü alındı. Klinikte tedavi uygulanabilen 15 olgu tedavi sonunda yeniden değerlendirildi. Çalışma grubunda viral etyolojiye yönelik serolojik göstergeler ile birlikte alanin aminotransferaz (ALT) ve aspartat aminotransferaz (AST) düzeyleri; serum MDA ve hepatit B virüs-DNA (HBV-DNA) düzeyleri araştırıldı. Karaciğer histopatolojik bulguları modifiye Knodell skorlamasına göre nekro-inflamatuvar aktivite (grade) ve fibroziz (stage) olarak skorlandı. Kronik hepatit B grubunun MDA düzeyleri kontrol grubuna göre istatistiksel olarak anlamlı düzeyde yüksek bulundu (p0.05). Tedavi edilen kronik hepatit B olgularında tedavi sonrası ortalama MDA düzeyleri, tedavi öncesi MDA düzeylerine göre istatistiksel olarak anlamlı düzeyde düşük bulundu (p

🔖

Cite This Article

KILIÇ, N., DENK, A., KALKAN, A., ÖZDEN, M. (2022). Relationship of serum malondialdehyde levels with histopathology and interferon treatment in HBeAg positive chronic hepatitis B cases. İnfeksiyon Dergisi, Cilt: 19 - Sayı: 1, 5–9. https://ajindex.com/articles/651741

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Juszczyk J. Clinical course and consequences of hepatitis B infection. Vaccine 2000; 18: 23-5
  2. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
  3. Rehermann B, Chisari FV. Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 2000; 242: 299-325
  4. Ferrari C, Bertoletti A, Penna A, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991; 88: 214-22
  5. Hilleman MR. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001; 19: 1837-48
  6. Robinson WS. Hepatitis B virus and hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000:1736-60
  7. Pietrangelo A. Metals, oxidative stres, and hepatic fibrogenesis. Semin Liver Dis 1996; 16: 13-30
  8. Schwarz KB. Oxidative stress during viral infection: a review. Free Radic Biol Med 1996; 21: 641-9
  9. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994; 41: 343-8
  10. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for accessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5
  11. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1978; 90: 37-43
  12. Yagi K. Assay for blood plasma or serum. Methods Enzymol 1984; 105: 328-31
  13. Boya P, de la Pena A, Beloqui O, et al. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol 1999; 31: 808-14
  14. Akkuş İ. Serbest Radikaller ve Fizyopatolojik Etkileri. Konya: Mimoza Yayınları, 1995: 1-47
  15. Cortan RS, Kumar V, Robbins SL. Robbins Pathologic Basis of Diseases. 4th ed. Phildelphia: WB Saunders Co, 1989: 1-38
  16. Kılıçturgay K. Viral hepatitte immünopatogenez. Tekeli E, Balık İ, ed. Viral Hepatit 2003’te. Ankara: Karakter Color AŞ, 2003: 316-28
  17. Serejo F, Emerit I, Filipe PM, et al. Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features. Can J Gastroenterol 2003; 17: 644-50.